Granisetron and ondansetron for prevention of nausea and vomiting in patients undergoing modified radical mastectomy.
Modified radical mastectomy is associated with a relatively high incidence of postoperative nausea and vomiting (PONV). This study was undertaken to evaluate the comparative profile and efficacy of ondansetron and granisetron to prevent PONV after modified radical mastectomy. In a randomized, double-blind, placebo-controlled trial, sixty female patients received ondansetron 4 mg, granisetron 1 mg or saline intravenously just before induction of anaesthesia (n = 20 for each group). A standardized general anaesthetic technique was employed. The incidence of PONV and adverse events were recorded for the first 24h postoperatively. The incidence of PONV was 25% with ondansetron, 20% with granisetron and 70% with saline (P < 0.05, Chi-square test with Yates' correction factor). The incidence of adverse events was comparable among the groups. Ondansetron and granisetron are both effective for reducing the incidence of PONV in female patients undergoing modified radical mastectomy.
Dua
N
N
Department of Anesthesiology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.
Bhatnagar
S
S
Mishra
S
S
Singhal
A K
AK
D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000768:Anesthesia, General; D001943:Breast Neoplasms / Q000175:diagnosis / Q000601:surgery*; D016009:Chi-Square Distribution; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D017829:Granisetron / Q000008:administration & dosage*; D006801:Humans; D007262:Infusions, Intravenous; D015411:Mastectomy, Modified Radical / Q000009:adverse effects* / Q000379:methods; D008875:Middle Aged; D009325:Nausea / Q000209:etiology / Q000517:prevention & control*; D017294:Ondansetron / Q000008:administration & dosage*; D011300:Preoperative Care; D011336:Probability; D012016:Reference Values; D018570:Risk Assessment; D016896:Treatment Outcome; D014839:Vomiting / Q000209:etiology / Q000517:prevention & control*
D017829:Granisetron; D017294:Ondansetron